搜尋結果
3 天前 · March 2022. Pfizer and BioNTech’s embrace of novel mRNA science played a pivotal role in achieving a record-breaking COVID-19 vaccine rollout. But a lesser-known part of this success story is Pfizer’s rapid adoption of new digital technologies to ensure the vaccine reached patients as safely and quickly as possible.
2 天前 · Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks ...
1 天前 · Ebbinghaus explained that both cancer vaccines and immunotherapies, such as Merck’s blockbuster Keytruda (pembrolizumab), act on the T cells, which fight cancer. “The way PD-1 inhibitors work is they take the brakes off of those cells. The vaccines work by presenting tumor-specific antigens to the immune system, which activates even more ...
4 天前 · Stock analysis for BioNTech SE (BNTX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
- 6.1K
5 天前 · A regimen of two doses of the Oxford–AstraZeneca vaccine followed by a booster dose of the Pfizer–BioNTech or the Moderna vaccine is initially about 60% effective against symptomatic disease caused by Omicron, then after 10 weeks the effectiveness drops to
2022年9月15日 · News. The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy...
4 天前 · Kara Rogers. Katalin Kariko, Hungarian-born biochemist known for her pioneering research into RNA therapeutics, particularly messenger RNA (mRNA) vaccines. Kariko’s investigation into the ability of mRNA to trigger immune responses in animals and humans greatly facilitated the development of the first mRNA vaccines.
